Sunshine Biopharma (NASDAQ: SBFM) details 2025 results and cost cuts
Rhea-AI Filing Summary
Sunshine Biopharma Inc. reported 2025 revenue of $36.3 million, a 4.1% increase from 2024, as it expanded its generic drug portfolio and advanced proprietary R&D programs. Gross profit rose to $12.26 million, while general and administrative expenses increased to $18.48 million, including a non-cash, non-recurring $1.75 million impairment charge on intangible assets.
The company recorded a net loss of $5.98 million for 2025, slightly higher than 2024. It raised $2.46 million in gross proceeds through a registered direct offering to support sales expansion and launched nine new generic prescription drugs. Management implemented cost-reduction initiatives in January 2026, which are expected to lower expenses by about $2 million to $3 million in 2026 as it works toward near-term profitability.
Positive
- None.
Negative
- None.
Insights
Moderate revenue growth, continued losses, and planned cost cuts define 2025.
Sunshine Biopharma delivered 2025 revenue of $36.31 million, up 4.1% from 2024, with gross profit improving to $12.26 million. This reflects steady expansion of its 71-product generic portfolio and nine additional generic launches across oncology, cardiovascular, CNS, and antimicrobial categories.
Operating costs remained heavy, with general and administrative expenses at $18.48 million, including a one-time, non-cash impairment charge of $1.75 million on intangible assets. Net loss widened modestly to $5.98 million, despite a $2.46 million registered direct offering that supported sales operations.
In January 2026, management initiated cost-reduction measures expected to cut expenses by about $2 million to $3 million during 2026, while continuing to fund proprietary programs such as the K1.1 mRNA liver cancer candidate and PLpro protease inhibitor for SARS-related infections. Future filings may clarify how these savings affect the path toward profitability.
8-K Event Classification
Key Figures
Key Terms
registered direct offering financial
impairment charge financial
gross profit financial
mRNA-Lipid Nanoparticle technical
PLpro protease inhibitor technical
forward-looking statements regulatory
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) | (IRS Employer ID No.) |
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
| The | ||
| The |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On April 6, 2026, Sunshine Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the year ended December 31, 2025. The press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: April 9, 2026 | SUNSHINE BIOPHARMA INC. |
| By: /s/ Dr. Steve N. Slilaty | |
Dr. Steve N. Slilaty, Chief Executive Officer |
| 3 |
Exhibit 99.1
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
FORT LAUDERDALE, FL / ACCESSWIRE / April 6, 2026 — Sunshine Biopharma Inc. (NASDAQ: SBFM) (“Sunshine Biopharma” or the “Company”), a pharmaceutical company offering and developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
2025 Highlights
| · | Revenue of $36.3 million, representing a 4.1% increase compared to 2024. | |
| · | $2.46 million in gross proceeds raised through a registered direct offering to support expansion of sales operations. | |
| · | Nine new generic prescription drugs launched, expanding the Company’s portfolio in oncology, cardiovascular health, central nervous system disorders, and antimicrobials. | |
| · | Advancement of proprietary antiviral research, including a new series of orally active, non-covalent PLpro protease inhibitors that demonstrated dose-dependent antiviral activity in SARS-CoV-2-infected mice, strong potency in cellular models, and favorable pharmacokinetics. |
Management Commentary
“We are pleased with our accomplishments in 2025, as we remain committed to reaching profitability in the near future,” said Dr. Steve Slilaty, CEO. “Looking ahead, we are excited about the opportunities for growth in 2026 and beyond as we continue expanding our generic drug portfolio and advancing our proprietary drug development programs to deliver more life-saving medicines to the market.”
Financial Summary (in millions)
| 2025 | 2024 | |||||||
| Revenue | $ | 36.31 | $ | 34.87 | ||||
| Gross Profit | $ | 12.26 | $ | 10.67 | ||||
| General & Administrative Expenses | $ | 18.48 | $ | 16.48 | ||||
| Net Loss | $ | 5.98 | $ | 5.13 | ||||
The increase in General & Administrative Expenses in 2025 was primarily driven by a non-cash, non-recurring impairment charge of $1.75 million related to intangible assets. Excluding this charge, the Company’s operating performance reflects a meaningful improvement over 2024.
In January 2026, Sunshine Biopharma implemented cost-reduction initiatives aimed at lowering general and administrative expenses and sharpening the Company’s focus on achieving near-term profitability. Based on current plans, these initiatives are expected to reduce expenses by approximately $2 million to $3 million in 2026, although there can be no assurance that these reductions will be fully realized.
| 1 |
About Sunshine Biopharma
Sunshine Biopharma currently markets 71 generic prescription drugs in Canada, with 12 additional launches planned for the remainder of 2026. The Company is also advancing two proprietary drug development programs:
| · | K1.1 mRNA, an mRNA-Lipid Nanoparticle therapeutic candidate targeting liver cancer. | |
| · | PLpro protease inhibitor, a small-molecule antiviral candidate for SARS-related coronavirus infections. |
Additional information is available at www.sunshinebiopharma.com.
Forward-Looking Statements
This press release contains forward-looking statements based on current expectations, forecasts, and assumptions that involve risks and uncertainties. These statements include, but are not limited to, those regarding the Company’s financial performance, drug development activities, and future growth opportunities. Actual results may differ materially due to various risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are encouraged to review the Company’s most recent SEC filings for additional information.
Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
| 2 |